Advertisement Spartan Bioscience and NorDiag sign new collaboration agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Spartan Bioscience and NorDiag sign new collaboration agreement

Spartan Bioscience, a molecular diagnostics company, and NorDiag, a biotechnology company, have signed a joint collaboration agreement with the intention of developing an end-to-end DNA preparation and analysis solution.

The goal of the partnership is to provide an end-to-end solution for DNA analysis that is truly fast, affordable and user friendly.

The basis of the collaboration is each company’s lab equipment which both have very small bench footprints and are easily portable. Pricing for individual systems is expected to be less than $15,000 each when both instruments are released in 2009.

Mark Kershey, vice president of corporate development at Spartan Bioscience, said: “The combination of the NorDiag ‘Arrow’ DNA isolation device with the Spartan DX-12 DNA analyzer has the potential to change the playing field in the DNA analysis space. With a combined price tag expected to be less than $30,000 there will be nothing else like it.”